623 related articles for article (PubMed ID: 32470562)
21. Involvement of shared mucosal-associated microbiota in the duodenum and rectum in diarrhea-predominant irritable bowel syndrome.
Li G; Yang M; Jin Y; Li Y; Qian W; Xiong H; Song J; Hou X
J Gastroenterol Hepatol; 2018 Jun; 33(6):1220-1226. PubMed ID: 29194775
[TBL] [Abstract][Full Text] [Related]
22. Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D.
Singh P; Alm EJ; Kelley JM; Cheng V; Smith M; Kassam Z; Nee J; Iturrino J; Lembo A
Gut Microbes; 2022; 14(1):2020067. PubMed ID: 35014601
[TBL] [Abstract][Full Text] [Related]
23. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
Duboc H; Rainteau D; Rajca S; Humbert L; Farabos D; Maubert M; Grondin V; Jouet P; Bouhassira D; Seksik P; Sokol H; Coffin B; Sabaté JM
Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
[TBL] [Abstract][Full Text] [Related]
24. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
Cash BD; Lacy BE; Rao T; Earnest DL
Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
[TBL] [Abstract][Full Text] [Related]
25. Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity.
Liu Z; Zhu S; He M; Li M; Wei H; Zhang L; Sun Q; Jia Q; Hu N; Fang Y; Song L; Zhou C; Tao H; Kao JY; Zhu H; Owyang C; Duan L
Chin Med J (Engl); 2022 Jul; 135(14):1716-1727. PubMed ID: 36070467
[TBL] [Abstract][Full Text] [Related]
26. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.
Carroll IM; Ringel-Kulka T; Siddle JP; Ringel Y
Neurogastroenterol Motil; 2012 Jun; 24(6):521-30, e248. PubMed ID: 22339879
[TBL] [Abstract][Full Text] [Related]
27. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome.
Tap J; Derrien M; Törnblom H; Brazeilles R; Cools-Portier S; Doré J; Störsrud S; Le Nevé B; Öhman L; Simrén M
Gastroenterology; 2017 Jan; 152(1):111-123.e8. PubMed ID: 27725146
[TBL] [Abstract][Full Text] [Related]
28. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.
Pimentel M; Cash BD; Lembo A; Wolf RA; Israel RJ; Schoenfeld P
Dig Dis Sci; 2017 Sep; 62(9):2455-2463. PubMed ID: 28589238
[TBL] [Abstract][Full Text] [Related]
29. Changes in Fecal Calprotectin After Rifaximin Treatment in Patients With Nonconstipated Irritable Bowel Syndrome.
Lee SH; Kim CR; Kim KN
Am J Med Sci; 2019 Jan; 357(1):23-28. PubMed ID: 30611316
[TBL] [Abstract][Full Text] [Related]
30. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
Mazzawi T; Hausken T; Hov JR; Valeur J; Sangnes DA; El-Salhy M; Gilja OH; Hatlebakk JG; Lied GA
Scand J Gastroenterol; 2019 Jun; 54(6):690-699. PubMed ID: 31190584
[No Abstract] [Full Text] [Related]
31. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
32. Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.
Brenner DM; Sayuk GS
Adv Ther; 2020 Jan; 37(1):83-96. PubMed ID: 31707713
[TBL] [Abstract][Full Text] [Related]
33. Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome.
Laterza L; Ianiro G; Scoleri I; Landi R; Bruno G; Scaldaferri F; Gaetani E; Campanale M; Gasbarrini A
Expert Opin Pharmacother; 2015 Mar; 16(4):607-15. PubMed ID: 25641072
[TBL] [Abstract][Full Text] [Related]
34. Rifaximin for the treatment of irritable bowel syndrome.
Cremonini F; Lembo A
Expert Opin Pharmacother; 2012 Feb; 13(3):433-40. PubMed ID: 22251066
[TBL] [Abstract][Full Text] [Related]
35. Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
Zhu X; Hong G; Li Y; Yang P; Cheng M; Zhang L; Li Y; Ji L; Li G; Chen C; Zhong C; Jin Y; Yang M; Xiong H; Qian W; Ding Z; Ning K; Hou X
Microbiol Spectr; 2021 Dec; 9(3):e0125521. PubMed ID: 34937163
[TBL] [Abstract][Full Text] [Related]
36. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
37. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial.
Ghoshal UC; Srivastava D; Misra A; Ghoshal U
Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):281-9. PubMed ID: 26731696
[TBL] [Abstract][Full Text] [Related]
38. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome.
Carroll IM; Ringel-Kulka T; Keku TO; Chang YH; Packey CD; Sartor RB; Ringel Y
Am J Physiol Gastrointest Liver Physiol; 2011 Nov; 301(5):G799-807. PubMed ID: 21737778
[TBL] [Abstract][Full Text] [Related]
39. Total Bilirubin Is Associated with Small Intestinal Bacterial Overgrowth in Diarrhea Predominant Irritable Bowel Syndrome.
Kim SY; Seo YS; Lee ES; Kim KN
Ann Clin Lab Sci; 2019 May; 49(3):344-352. PubMed ID: 31308034
[TBL] [Abstract][Full Text] [Related]
40. Prolonged Intake of Luvos Healing Earth does not alter the Composition of the Gut Microbiota in Patients with Diarrhea-predominant Irritable Bowel Syndrome and Healthy Controls.
Vasapolli R; Krikonas S; Macke L; Gravdal K; Kirste KH; Casén C; Storr M; Malfertheiner P; Schulz C
J Gastrointestin Liver Dis; 2024 Mar; 33(1):30-36. PubMed ID: 38554421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
